Relypsa (RLYP) Has Multiple Banking Relationships
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/19/2024
- Nasdaq, S&P tumble as Netflix, chip stocks drag; AmEx boosts Dow
- Sony/Apollo bid for Paramount could be worth as much as $29 billion - Source
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Nasdaq tumbles, Treasuries dip amid earnings, geopolitical crosscurrents
- Gold prices rally past $2,400 on reports of Israel strikes on Iran
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Jabil falls after placing CEO on paid leave amid internal investigation
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
Wedbush Reiterates Bullish Stance on Relypsa (RLYP) Following Veltassa MoM Acceleration
April 18, 2016 11:47 AM EDTIn a note Friday, Wedbush analyst Liana Moussatos reiterated her Outperform rating and $52 price target on Relypsa, Inc. (NASDAQ: RLYP) after the third full month of Veltassa launch metrics shows month-over-month acceleration.
In March, 1,277 (+57% MoM) new patients started taking Veltassa with a free starter supply, 706 (+102% MoM) outpatient prescriptions were filled, and 201 (+14% MoM) hospital/institution units were sold.
Veltassa's early launch continues to track... More
BTIG Trims Q1 Sales Outlook on Relypsa's (RLYP) Veltassa Following Recent Update; Affirms at 'Buy'
April 15, 2016 2:44 PM EDTBTIG affirms Relypsa, Inc. (Nasdaq: RLYP) with a Buy rating and $45 price target after the company disclosed new patient starts, outpatient prescriptions and... More
Mizuho Weighs in on Relypsa (RLYP) Veltassa Numbers and Latest on M&A
April 15, 2016 9:59 AM EDTMizuho Securities analyst Irina Koffler weighed in on Relypsa, Inc. (NASDAQ: RLYP) following today's Veltassa prescriptions numbers and the latest M&A speculation.
Koffler noted that Veltassa prescriptions sold were in-line with their estimates. "Relypsa released March's Veltassa numbers, and reported 1,277 patients received a free starter supply of Veltassa, 706 retail prescriptions were filled, and 201 hospital packs were sold. In all, a total of 907 prescriptions/units were reimbursed. This compares to our estimates of 1,624 patients receiving the starter kit, 700 retail TRx's... More
